GSK Plunges on Further Avandia Woes

Weak sales of the diabetes drug and competition from generics lead pharma giant GlaxoSmithKline to warn shareholders that earnings will fall

A shock profit warning from GlaxoSmithKline sent its shares plummeting yesterday after the drug giant said "the shadow of Avandia would continue to make life difficult" in 2008.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.